A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Amer M. Zeidan, Rory M. Shallis et al.|Annals of Hematology|2023Cited by 23
Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscriptsTed M. Getz, Klaus H. Metzeler, Amy E. DeZern et al.|Blood|2025Cited by 0